All posts tagged
The Advantage for the First Mover in NASH is Limited, says Genfit
Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy
Two Big Pharma Players Team up to Take Over the NASH Space
Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Not to be Underestimated: What’s the Hype around NASH?
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Green Light for Genfit to Tackle another Liver Disease
Genfit raises €45M and gets Closer to the First NASH Cure
Genfit’s Non-Invasive Diagnostic could unlock the NASH Market
Beyond NASH: Genfit jumps into another Critical Liver Condition
Genfit Has Enroled its First Patient in a NASH Phase III Trial
Genfit Raises almost €50M for a Liver Drug to Advance to Phase III Trials
Labiotech UG, All Rights Reserved -
Send this to a friend